APA (7th ed.) Citation

AMS, S., DL, W., C, H., PN, M., M, A., VN, B., . . . S, A. (2023). Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 168, 115793. https://doi.org/10.1016/j.biopha.2023.115793

Chicago Style (17th ed.) Citation

AMS, Shein, et al. "Novel Intranasal Phage-CaEDTA-ceftazidime/avibactam Triple Combination Therapy Demonstrates Remarkable Efficacy in Treating Pseudomonas Aeruginosa Lung Infection." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 168 (2023): 115793. https://doi.org/10.1016/j.biopha.2023.115793.

MLA (9th ed.) Citation

AMS, Shein, et al. "Novel Intranasal Phage-CaEDTA-ceftazidime/avibactam Triple Combination Therapy Demonstrates Remarkable Efficacy in Treating Pseudomonas Aeruginosa Lung Infection." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 168, 2023, p. 115793, https://doi.org/10.1016/j.biopha.2023.115793.